JOP20200024A1 - Dihydrooxadiazinones - Google Patents
DihydrooxadiazinonesInfo
- Publication number
- JOP20200024A1 JOP20200024A1 JOP/2020/0024A JOP20200024A JOP20200024A1 JO P20200024 A1 JOP20200024 A1 JO P20200024A1 JO P20200024 A JOP20200024 A JO P20200024A JO P20200024 A1 JOP20200024 A1 JO P20200024A1
- Authority
- JO
- Jordan
- Prior art keywords
- compounds
- aforementioned
- dihydrooxadiazinones
- diseases
- dihydroxydiazinone
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- CWADBNYOBWCBMX-UHFFFAOYSA-N OC(OP(=S)(OC(C)O)OC1=NC(=NC(=C1)C)C(C)C)C Chemical class OC(OP(=S)(OC(C)O)OC1=NC(=NC(=C1)C)C(C)C)C CWADBNYOBWCBMX-UHFFFAOYSA-N 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
- C07D273/04—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
مركبات ثنائي هيدروكساديازينون الملخص يزود الاختراع الحالي مركبات ثنائي هيدروكسي ديازينون بالصيغة العامة (I): " معادلة" (I)، حيث R1، R2، R3، و R4 كما هي معرفة هنا، طرق لتحضير المركبات المذكورة، مركبات وسيطة مفيدة لتحضير المركبات المذكورة، تراكيب صيدلانية وتوليفات تتضمن المركبات المذكورة واستخدام المركبات المذكورة لتصنيع تراكيب صيدلانية لعلاج أو الوقاية من الأمراض، وتحديداً أمراض فرط التكاثر، في صورة عامل وحيد أوDihydroxadiazinon Compounds Abstract The present invention provides dihydroxydiazinone compounds with the general formula (I): “Equation” (I), where R1, R2, R3, and R4 as defined herein, methods for preparing the said compounds, useful intermediaries for the preparation of the said compounds, Pharmaceutical formulations and combinations that include the aforementioned compounds and the use of the aforementioned compounds to manufacture pharmaceutical formulas to treat or prevent diseases, specifically hyperproliferative diseases, in the form of a single agent or
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762541627P | 2017-08-04 | 2017-08-04 | |
| PCT/EP2018/071039 WO2019025562A1 (en) | 2017-08-04 | 2018-08-02 | Dihydrooxadiazinones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20200024A1 true JOP20200024A1 (en) | 2020-02-02 |
Family
ID=63207725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2020/0024A JOP20200024A1 (en) | 2017-08-04 | 2018-08-01 | Dihydrooxadiazinones |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US11427553B2 (en) |
| EP (1) | EP3661517B1 (en) |
| JP (2) | JP7676141B2 (en) |
| KR (1) | KR20200036914A (en) |
| CN (1) | CN111212647B (en) |
| AR (1) | AR112402A1 (en) |
| AU (1) | AU2018309356B2 (en) |
| BR (1) | BR112020002351A2 (en) |
| CA (1) | CA3071800A1 (en) |
| CL (1) | CL2020000303A1 (en) |
| CO (1) | CO2020001242A2 (en) |
| CR (1) | CR20200057A (en) |
| CU (1) | CU24608B1 (en) |
| EA (1) | EA202090448A1 (en) |
| EC (1) | ECSP20008441A (en) |
| IL (1) | IL272098B2 (en) |
| JO (1) | JOP20200024A1 (en) |
| MA (1) | MA49750A (en) |
| MX (1) | MX2020001404A (en) |
| PE (1) | PE20200936A1 (en) |
| PH (1) | PH12020500134A1 (en) |
| SG (1) | SG11201913775UA (en) |
| TW (1) | TWI791581B (en) |
| UA (1) | UA125731C2 (en) |
| UY (1) | UY37832A (en) |
| WO (1) | WO2019025562A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200024A1 (en) | 2017-08-04 | 2020-02-02 | Bayer Ag | Dihydrooxadiazinones |
| EP3661917B1 (en) | 2017-08-04 | 2022-05-11 | Bayer Aktiengesellschaft | 6-((3-trifluoromethyl)phenyl)-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancer |
| TW202031677A (en) | 2018-11-01 | 2020-09-01 | 美商博得學院股份有限公司 | Identification of pde3 modulator responsive cancers |
| WO2020157188A1 (en) * | 2019-02-01 | 2020-08-06 | Bayer Aktiengesellschaft | Dihydrooxadiazinones for the treatment of hyperproliferative diseases |
| AU2020215088A1 (en) | 2019-02-01 | 2021-07-22 | Bayer Aktiengesellschaft | 1,2,4-triazin-3(2H)-one compounds for the treatment of hyperproliferative diseases |
| CN117279644A (en) | 2021-03-03 | 2023-12-22 | 拜耳股份有限公司 | Substituted 3,6-dihydro-2H-1,3,4-oxadiazin-2-ones for the treatment of sarcomas |
| EP4289828A1 (en) | 2022-06-10 | 2023-12-13 | Bayer Aktiengesellschaft | Method for the preparation of a 3,6-dihydro-2h-1,3,4-oxadiazin-2-one |
| EP4289829A1 (en) | 2022-06-10 | 2023-12-13 | Bayer Aktiengesellschaft | Crystalline forms of (6s)-5-[4'-fluoro-2-(trifluoromethyl)biphenyl-4-yl]-6-methyl-3,6-dihydro- 2h-1,3,4-oxadiazin-2-one |
| CN120187704A (en) * | 2022-11-24 | 2025-06-20 | 盛睿泽华医药科技（苏州）有限公司 | Pyridone compound and preparation method and use thereof |
| CN117903077B (en) * | 2023-01-13 | 2024-09-03 | 上海超阳药业有限公司 | Dihydrooxadiazinone compounds and their applications |
| CN118420559B (en) * | 2023-04-27 | 2025-02-14 | 上海超阳药业有限公司 | Deuterated oxadiazinone compounds and uses thereof |
| CN118047833B (en) * | 2024-01-31 | 2025-03-14 | 海南大学 | Ferrocene-containing substituted amino acetamides compound and preparation method and application thereof |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4097671A (en) * | 1975-08-28 | 1978-06-27 | General Electric Company | Dihydrooxadiazinones and method for making |
| US4052395A (en) | 1975-09-11 | 1977-10-04 | Sankyo Company Limited | Agricultural fungicidal compositions containing 6-(substituted phenyl)-pyridazinones and said pyridazinones |
| US4258094A (en) * | 1979-04-26 | 1981-03-24 | Brunswick Corporation | Melt bonded fabrics and a method for their production |
| US4334030A (en) | 1979-11-23 | 1982-06-08 | General Electric Company | Thermoplastic foamable blends |
| DE3172252D1 (en) | 1980-11-14 | 1985-10-17 | Ici Plc | Heterocyclic compounds |
| DE3263497D1 (en) | 1981-03-04 | 1985-06-20 | Ciba Geigy Ag | Pyridazinones, method for their preparation, pharmaceutical compositions containing these compounds and their use |
| ZA827641B (en) | 1981-11-12 | 1983-09-28 | Ici Plc | Thiadiazine, oxadiazine and triazine derivatives which possess cardiotonic and/or antihypertensive activity |
| US4495185A (en) | 1981-11-12 | 1985-01-22 | Imperial Chemical Industries, Plc | 1,2,4-Triazin-3(2H) ones |
| US4581356A (en) | 1983-03-22 | 1986-04-08 | Fujisawa Pharmaceutical Co., Ltd. | Triazine derivatives, and pharmaceutical compositions comprising the same |
| GB8310435D0 (en) | 1983-04-18 | 1983-05-25 | Fujisawa Pharmaceutical Co | Triazine derivatives |
| JPS59196874A (en) | 1983-04-22 | 1984-11-08 | Fujisawa Pharmaceut Co Ltd | Triazine derivative, its preparation, and drug composition containing it |
| JPS6153270A (en) | 1984-08-17 | 1986-03-17 | チバ・ガイギー・アクチエンゲゼルシヤフト | Substituted pyridazinone, manufacture and medicine |
| US4816454A (en) | 1984-09-21 | 1989-03-28 | Cassella Aktiengesellschaft | 4,5-dihydro-3(2H)-pyridazinones and their pharmacological use |
| GB8426804D0 (en) | 1984-10-23 | 1984-11-28 | Ciba Geigy Ag | Pyridazinones preparations |
| DE3677316D1 (en) | 1985-10-17 | 1991-03-07 | Smith Kline French Lab | 4 (4-OXO-1,4-DIHYDROPYRIDIN-1-YL) PHENYL DERIVATIVES. |
| EP0303418A3 (en) | 1987-08-11 | 1990-11-07 | Smithkline Beecham Laboratoires Pharmaceutiques | Substituted indolones, useful in the treatment of heart or asthmatic diseases |
| ATE180475T1 (en) | 1990-09-21 | 1999-06-15 | Rohm & Haas | DIHYDROPYRIDAZINONES AND PYRIDAZINONES AS FUNGICIDES |
| JPH0676325B2 (en) * | 1992-05-08 | 1994-09-28 | 三井東圧化学株式会社 | Antithrombotic agent containing an oxadiazine derivative as an active ingredient |
| JPH07508987A (en) | 1992-07-01 | 1995-10-05 | オーソ・フアーマシユーチカル・コーポレーシヨン | 1-arylsulfonyl, arylcarbonyl and 1-arylphosphonyl-3-phenyl-1,4,5,6-tetrahydropyridazine |
| JPH07291968A (en) | 1994-04-26 | 1995-11-07 | Mitsubishi Chem Corp | Triazinone derivative or salt thereof |
| DE19929787A1 (en) * | 1999-06-29 | 2001-01-04 | Bayer Ag | New 4- (2-oxodihydrooxadiazinylphenyl) amides and their use |
| EP1368035A1 (en) * | 2001-02-12 | 2003-12-10 | MERCK PATENT GmbH | Use of type 4 phosphodiesterase inhibitors in myocardial diseases |
| WO2008108602A1 (en) | 2007-03-07 | 2008-09-12 | Dong-A Pharm. Co., Ltd. | Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same |
| CN101538245B (en) | 2008-03-18 | 2011-02-16 | 中国科学院上海药物研究所 | One-class pyridazinone compounds and preparation method and application thereof |
| US9212146B2 (en) | 2008-03-18 | 2015-12-15 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Substituted pyridazinones for the treatment of tumors |
| CA2758774C (en) | 2009-04-15 | 2015-02-03 | Research Triangle Institute | Monoamine reuptake inhibitors |
| FR2948940B1 (en) * | 2009-08-04 | 2011-07-22 | Servier Lab | NOVEL DIHYDROINDOLONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| JP5794297B2 (en) | 2010-05-07 | 2015-10-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Pyridazinone as a GPR119 agonist |
| EP2675440B1 (en) | 2011-02-14 | 2020-03-25 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| TWI532742B (en) | 2011-02-28 | 2016-05-11 | 艾伯維有限公司 | Tricyclic inhibitors of kinases |
| WO2014164704A2 (en) | 2013-03-11 | 2014-10-09 | The Broad Institute, Inc. | Compounds and compositions for the treatment of cancer |
| TWI656121B (en) * | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | 2-(morpholin-4-yl)-1,7-naphthyridine |
| WO2017027854A1 (en) * | 2015-08-13 | 2017-02-16 | The Broad Institute, Inc. | Compositions and methods for cancer expressing pde3a or slfn12 |
| US10729680B2 (en) | 2016-01-14 | 2020-08-04 | Bayer Pharma Aktiengesellschaft | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines |
| TW201733591A (en) | 2016-02-05 | 2017-10-01 | 拜耳製藥公司 | Compounds, compositions and methods for cancer patient grading and cancer treatment |
| KR101831772B1 (en) * | 2016-03-24 | 2018-03-06 | 아이디에스(주) | Camera close-up device with complex light source module and shooting mehtod for finger print specimen by the same |
| TWI808055B (en) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-1 inhibitors |
| TWI794171B (en) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-l1 inhibitors |
| JOP20200024A1 (en) | 2017-08-04 | 2020-02-02 | Bayer Ag | Dihydrooxadiazinones |
| EP3661917B1 (en) | 2017-08-04 | 2022-05-11 | Bayer Aktiengesellschaft | 6-((3-trifluoromethyl)phenyl)-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancer |
| TW202031677A (en) | 2018-11-01 | 2020-09-01 | 美商博得學院股份有限公司 | Identification of pde3 modulator responsive cancers |
| AU2020215088A1 (en) | 2019-02-01 | 2021-07-22 | Bayer Aktiengesellschaft | 1,2,4-triazin-3(2H)-one compounds for the treatment of hyperproliferative diseases |
-
2018
- 2018-08-01 JO JOP/2020/0024A patent/JOP20200024A1/en unknown
- 2018-08-02 EP EP18755153.6A patent/EP3661517B1/en active Active
- 2018-08-02 AU AU2018309356A patent/AU2018309356B2/en not_active Ceased
- 2018-08-02 UA UAA202001558A patent/UA125731C2/en unknown
- 2018-08-02 BR BR112020002351-5A patent/BR112020002351A2/en not_active IP Right Cessation
- 2018-08-02 SG SG11201913775UA patent/SG11201913775UA/en unknown
- 2018-08-02 EA EA202090448A patent/EA202090448A1/en unknown
- 2018-08-02 CN CN201880050751.0A patent/CN111212647B/en active Active
- 2018-08-02 KR KR1020207005998A patent/KR20200036914A/en not_active Withdrawn
- 2018-08-02 CA CA3071800A patent/CA3071800A1/en active Pending
- 2018-08-02 WO PCT/EP2018/071039 patent/WO2019025562A1/en not_active Ceased
- 2018-08-02 JP JP2020505898A patent/JP7676141B2/en active Active
- 2018-08-02 CU CU2020000008A patent/CU24608B1/en unknown
- 2018-08-02 MX MX2020001404A patent/MX2020001404A/en unknown
- 2018-08-02 PE PE2020000184A patent/PE20200936A1/en unknown
- 2018-08-02 MA MA049750A patent/MA49750A/en unknown
- 2018-08-02 US US16/635,504 patent/US11427553B2/en active Active
- 2018-08-02 CR CR20200057A patent/CR20200057A/en unknown
- 2018-08-03 TW TW107127172A patent/TWI791581B/en not_active IP Right Cessation
- 2018-08-03 AR ARP180102218 patent/AR112402A1/en not_active Application Discontinuation
- 2018-08-03 UY UY0001037832A patent/UY37832A/en not_active Application Discontinuation
-
2020
- 2020-01-16 IL IL272098A patent/IL272098B2/en unknown
- 2020-01-17 PH PH12020500134A patent/PH12020500134A1/en unknown
- 2020-02-04 CL CL2020000303A patent/CL2020000303A1/en unknown
- 2020-02-04 EC ECSENADI20208441A patent/ECSP20008441A/en unknown
- 2020-02-04 CO CONC2020/0001242A patent/CO2020001242A2/en unknown
-
2022
- 2022-07-11 US US17/862,255 patent/US12258323B2/en active Active
- 2022-07-14 US US17/865,236 patent/US11773070B2/en active Active
-
2023
- 2023-06-13 JP JP2023097166A patent/JP2023115065A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP19030002A (en) | 1,2,4-TRIAZOLONES 2,4,5-TRISUSTITUIDED | |
| JOP20170135A1 (en) | Diazaspiroalkylmethyl-indoles | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| UA109220C2 (en) | DERIVATIVES (4-PHENYLIMIDAZOL-2-IL) ETHYLAMINE AS SODIUM CHANNEL MODULATORS | |
| TR201904455T4 (en) | 1,2,4-triazoles and their uses as nuclear transport modulators. | |
| TN2017000467A1 (en) | Amido-substituted cyclohexane derivatives | |
| JOP20170126A1 (en) | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxylamide compounds | |
| EA201591890A1 (en) | DERIVATIVES N-PHENYLCARBOXAMIDE AND THEIR USE AS A MEDICINE PREPARATION FOR THE TREATMENT OF HEPATITIS B | |
| NZ768368A (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| MX2015011984A (en) | Dihydro-pyrrolopyridinone bromodomain inhibitors. | |
| PH12020500134A1 (en) | Dihydrooxadiazinones | |
| MX359882B (en) | AMIDAS AS MODULATORS OF SODIUM CHANNELS. | |
| EA201790306A1 (en) | 2- (MORFOLIN-4-IL) -1,7-NAFTYRIDINES | |
| JOP20190193A1 (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| EA201592200A1 (en) | DERIVATIVES OF SULFAMOILPYRROLAMIDE AND THEIR APPLICATION AS MEDICINES FOR THE TREATMENT OF HEPATITIS B | |
| MX2019012847A (en) | C5-anilinoquinazoline compounds and their use in treating cancer. | |
| DOP2015000245A (en) | DERIVATIVES OF 3-ACETYLLAMIN-1 (PHENYL-HETEROARIL-AMINOCARBONIL OR PHENYL-HETEROARIL-CARBONYLAMINE) BENZENE FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | |
| CY1116057T1 (en) | KINAZOLIN-4 (3H) -ONE DERIVATIVES USED AS RI3 | |
| EA201891063A1 (en) | DERIVATIVES OF DIHYDROIMIDAZOPIRAZINONE APPLICABLE IN THE TREATMENT OF CANCER | |
| UY37973A (en) | MACROCYCLIC INDOL DERIVATIVES | |
| EA201591541A1 (en) | BETA SECRETASE INHIBITORS 1 (BACE 1) | |
| UY36257A (en) | "IMIDAZOPIRIDAZINE COMPOUNDS". | |
| UY37250A (en) | INDOL MACROCYCLIC DERIVATIVES | |
| JOP20200100A1 (en) | Pyrazolo-pyrrolo-pyrimidine-diene derivatives are new as P2X3 inhibitors | |
| UY37972A (en) | MACROCYCLIC INDOL DERIVATIVES SUBSTITUTED WITH CHLORINE |